Phase 1 solid tumor biotechnology company Aktis Oncology (AKTS.US) applies for a US stock IPO to raise $100 million

The Zhitong Finance App learned that Aktis Oncology (AKTS.US), a phase I biotech company focused on developing radiopharmaceuticals targeting solid tumors, submitted an application to the US Securities and Exchange Commission (SEC) last Friday to raise up to 100 million US dollars through an initial public offering (IPO).

According to reports, Aktis Oncology is a clinical-stage oncology pharmaceutical company. The core research direction is alpha particle-emitting radiopharmaceuticals for the treatment of high-incidence solid tumors. In the company's pipeline, AC-AKY-1189 is suitable for cancer that targets nectin-4 protein. A multi-center clinical phase Ib trial is currently being carried out in the US, with about 150 patients enrolled. Preliminary clinical data is expected to be released in the first quarter of 2027; another drug candidate, AC-AKY-2519, targets tumors expressing B7-H3 protein, and a new drug clinical trial application (IND) is scheduled to be submitted in 2026. In addition, the company has established isotope supply partnerships with many domestic and foreign institutions, and its internal production facilities that meet the Pharmaceutical Production Quality Management Specification (cGMP) are expected to be put into operation in 2026; at the same time, the company is also carrying out cooperative research to lay out more microprotein-radio-conjugated drug projects.

The company, headquartered in Boston, Massachusetts, USA, was founded in 2020 and achieved revenue of $6 million in the 12 months ending September 30, 2025. The company plans to be listed on the NASDAQ under the stock code AKTS. The joint bookkeepers of this IPO include J.P. Morgan Chase, Bank of America Securities, Leerink Partners, and TD Cowen. The specific offering pricing terms have not been disclosed to the public.